Vaccinia virus as an expression vector.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
M E Perkus
Publications and source records attributed to M E Perkus.
Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
Vaccinia virus recombinants containing herpes simplex virus (HSV) type 1 (VP176) or type 2 (VP221) glycoprotein D (gD) genes were studied for their protective potential in the guinea pig model of recurrent HSV type 2 disease. Cells infected with these recombinants synthesized at least one protein (precursor, mature form, or both) that was precipitated with monoclonal antibody to HSV type-common determinants on gD. These determinants were detected on the surface of cells infected with the recombinants at 2 hr after infection. VP176 immunization protected against primary (P much less than .001) and recurrent (P much less than .001) cutaneous HSV type 2 lesions and ganglionic latency (62% protection). VP221 immunization protected against recurrent disease (P less than .05), although HSV type 2 ganglionic infection was established. Protection, first observed at two weeks after immunization, apparently did not involve HSV-specific neutralizing antibody because seroconversion was detected at 35-45 days after immunization. Protection was correlated with HSV-specific lymphoproliferation and the elaboration of lymphokines that enhance natural killer cell cytolysis.
Animals↗
Insertion and deletion mutants of vaccinia virus.
Thirteen viable insertion mutants of vaccinia virus have been constructed. These mutants, containing coding sequences of the herpes simplex virus thymidine kinase (HSV-TK) gene, were generated by marker transfer via in vivo recombination. The mutants were identified using a replica filter plating technique by in situ hybridization using 32P-nick translated HSV-TK sequences and obtained as pure cultures by repeated plaque purification. Some of these insertion mutants were in turn used as substrates to generate viable deletion mutants of vaccinia virus in the presence of 5'-bromodeoxyuridine. An example of this approach resulting in a vaccinia virus deleted of approximately 1.5 kb of nonessential DNA is presented. Furthermore, the analysis of spontaneously occurring viable deletion mutants of vaccinia lacking approximately 21.4 kb of nonessential DNA is described.
Animals↗
Recombinant vaccinia virus: immunization against multiple pathogens.
The coding sequences for the hepatitis B virus surface antigen, the herpes simplex virus glycoprotein D, and the influenza virus hemagglutinin were inserted into a single vaccinia virus genome. Rabbits inoculated intravenously or intradermally with this polyvalent vaccinia virus recombinant produced antibodies reactive to all three authentic foreign antigens. In addition, the feasibility of multiple rounds of vaccination with recombinant vaccinia virus was demonstrated.
Animals↗
Live recombinant vaccines using genetically engineered vaccinia virus.
Explore the source record for details and available documents.
Animals↗
Mapping the genes in the terminal redundancy of bacteriophage SPO1 with restriction endonucleases.
Although most early transcription from SPO1, a lytic DNA bacteriophage of Bacillus subtilis, is specified by the 12.6-kilobase region of the terminal redundancy, early genes from this region have not been identified by standard genetic means. We mapped genes to DNA regions of the SPO1 terminal redundancy by analyzing in vitro protein synthesis from isolated SPO1 restriction fragments in an Escherichia coli-coupled transcription-translation cell-free system. DNA from the terminal redundancy directs the synthesis in vitro of eleven proteins, e3, e4, e6, e7, e9, e12, e15, e16, e18, e20, and e21, which correspond in mobility on sodium dodecyl sulfate-polyacrylamide gels with authentic SPO1 early proteins. From their mapped positions on the DNA, genes were positioned downstream from most, but not all, of the twelve early promoter regions identified in vitro in the terminal redundancy. The temporal patterns of early protein synthesis in vivo suggest a differential turning on and off of early promoters in the terminal redundancy. Both in vivo and in vitro evidence suggests the existence of previously unidentified early promoter regions upstream from the genes for e6 and e4 as well as a middle promoter region upstream from the gene for e16.
Bacillus subtilis↗